Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single Center Study to Assess the Safety of MB66, a Combined Anti-HIV (VRC01-N) and Anti-HSV (HSV8-N) Monoclonal Antibody Film for Vaginal Application as Microbicide

NCT02579083 is registered in ClinicalTrials.gov with KBio Inc as lead sponsor.

NCT NCT02579083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02579083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single Center Study to Assess the Safety of MB66, a Combined Anti-HIV (VRC01-N) and Anti-HSV (HSV8-N) Monoclonal Antibody Film for Vaginal Application as Microbicide
Lead sponsor
KBio Inc
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2016
Completion date
July 31, 2018
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

herpes simplex infections, hiv